This editorial refers to 'Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration' by D.K. Jagadeesha et al., pp. 406-413, this issue.
The Nox family of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases is an important source of reactive oxygen species (ROS). They comprise a group of transmembrane proteins possessing six transmembrane domains with conserved binding sites for FAD and NADPH and four haem-binding histidines in the third and fifth transmembrane domains whose function is to produce ROS by transferring an electron to molecular oxygen. This process yields superoxide anions (O 2 2 ), which can further react to hydrogen peroxide (H 2 O 2 ) or, in the presence of nitric oxide (NO), to peroxynitrite (ONOO 2 ). Although ROS can be highly reactive and oxidize proteins, DNA, and lipids, they are now considered important signalling molecules in their own right, modulating cellular processes such as gene expression, proliferation, and migration. 1 NADPH oxidases are critical determinants of the redox status of the vessel wall and are important in the pathophysiology of atherosclerosis. 1 In vascular cells, the NADPH oxidase isoforms Nox1, Nox2, Nox4, and Nox5 are expressed and differ in their activity, response to stimuli, and the type of ROS released. 1 Much attention has focused on the roles of different Nox isoforms in ROS generation in vascular smooth muscle cells (VSMC) and the resulting changes in phenotype and fate. 1 However, the intracellular signalling events by which NADPH oxidase-generated ROS modulate VSMC function and atherogenesis have yet to be elucidated. In this context, Jagadeesha et al. 2 demonstrate for the first time that Nox1 NADPH oxidase transduces its signal in VSMC through a novel c-Src-mediated transactivation of the epidermal growth factor receptor (EGFR) to activate matrix metalloproteinase 9 (MMP-9) and promote VSMC migration in vitro. Previous studies had linked Nox1 to VSMC phenotypic changes, including angiotensin II-induced hypertrophy, 3 serum-induced proliferation, 4 and basic fibroblast growth factor (bFGF)-induced migration. 5 In addition, Nox1-derived ROS may participate in neointimal formation by mediating PDGF-induced signalling. 6 Jagadeesha et al. 2 further addressed the potential involvement of thrombin-induced, NADPH oxidase-induced ROS and downstream cell-cell adhesion by the cadherin:catenin complex 7 in the regulation of VSMC behaviour, using multiple approaches to modify the expression of Nox1 in VSMC. Their data clearly identify steps in the signalling cascade by which Nox1-dependent ROS generation contributes to VSMC migration in vitro. These steps include (i) Nox1-dependent transactivation of EGFR via c-Src; (ii) transactivation of EGFR leading to ERK1/2 phosphorylation; (iii) Nox1-dependent EGFR transactivation leading to MMP-9 activation via ERK1/2 phosphorylation, and (iv) Nox1/EGFR/MMP-9-induced N-cadherin shedding. As arterial injury and atherosclerotic lesions are characterized by enhanced thrombin expression and activity, increased Nox activity, and increased ROS production, 8 activation of this signalling cascade by thrombin identifies one potential mechanism by which Nox1-derived ROS may promote intimal vascular disease. Because others have delineated many of the growth-related signalling pathways associated with Nox1, the study by Jagadeesha et al. 2 focused primarily on understanding the mechanisms by which Nox1 regulates VSMC migration. Changes in N-cadherin-mediated cellcell adhesion and intimal thickening have already been shown to involve matrix-degrading MMP-dependent shedding of the extracellular portion of N-cadherin, leading to increased VSMC proliferation via elevation of b-catenin signalling and cyclin D1 expression. 9 The current study is the first demonstration of a similar mechanism responsible for thrombin stimulation of VSMC migration. The study also suggests a putative role for Nox1 in the tonic activation of MMP-9 and subsequent shedding of N-cadherin from the membrane in un-stimulated VSMC. While it is clear that Nox1 controls N-cadherin shedding in the current study, it is not as clear that this mechanism is exclusively responsible for thrombin-induced VSMC migration. Migration is an integrated, dynamic, and cyclical process dependent upon orchestrated control of regulators of the actin cytoskeleton, including cofilin. Cofilin is a major effector of Nox1-
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mediated VSMC migration in vitro and is reduced in Nox1-deficient (Nox1 2/2) cells under both basal and PDGF-stimulated conditions. 10 Further work is required to clarify whether a diminished cofilin/ MMP-9 axis is responsible for the impaired migratory response of Nox1 2 -deficient cells 6 in response to thrombin. Future studies might also clarify whether thrombin-stimulated, Nox-induced ROS engage a Slingshot-1L (SSH-1L)-cofilin pathway to regulate cytoskeletal organization and VSMC migration within vascular lesions. 11 Moreover, since Nox also plays a critical role in the regulation of both CD44 and HA expression in VSMC treated with thrombin, 8 it is tempting to speculate that the reported increase in plasma sCD44 levels in apoE 2/2 mice is due to proteolytic cleavage of membrane-anchored CD44 following Nox1-mediated stimulation of MMP-9. If this is the case, Nox1-based NADPH oxidase inhibitors may attenuate CD44 and HA expression in apoE 2/2 mice and decrease not only the oxidative stress but also the migratory VSMC phenotype typical of atherosclerosis.
Whereas both c-Jun-N-terminal kinase (JNK) and Src/ phosphoinositide-dependent kinase-1 (PDK1)/PAK regulated bFGFand PDGF-induced, Nox1-dependent migration of VSMC, 5, 12 respectively, thrombin-induced VSMC migration appeared until now dependent on ROS-regulated p38 MAPK activation. 13 In the current study, a role for EGFR transactivation by c-Src following thrombin stimulation is supported since thrombin-induced phosphorylation of Src and subsequent transactivation of the EGFR at multiple tyrosine residues was absent in Nox1-deficient cells. Additionally, as Nox1 activation of c-Src was upstream of EGFR phosphorylation, a role for Nox1 in the redox sensitivity of multiple tyrosine residues within EGFR is strongly implicated. Indeed, this group had previously reported a novel mechanism by which extracellular oxidative stress increases expression and activity of Nox1 NADPH oxidase and contributes to vascular disease through transactivation of EGFR and subsequent activation of the MEK/ERK pathway. 14 The current in vitro study now suggests that thrombin-induced Nox1 activity and transactivation of EGFR requires c-Src activation, leading to ERK1/2 phosphorylation, activation of MMP-9, and promotion of VSMC migration. It remains to be seen whether this in vitro signalling cascade operates in vivo under physiological or pathophysiological conditions. Of note, however, are studies demonstrating no changes in Src, p38 MAPK, or JNK in response to PDGF in wild-type or Nox1-deficient cells, suggesting that migratory signalling following injury may well be agonistand/or Nox-specific. 6 Overall, Jagadeesha et al. provide an exciting insight into the molecular mechanisms by which thrombin, through Nox1 generation of ROS, may promote vascular lesion formation. Whereas both the mechanism by which Nox1 promotes VSMC migration via N-cadherin shedding and the role of N-cadherin in modulating VSMC migration remain controversial, 15 other, yet undefined, pathways may also be involved. Nevertheless, specific inhibitors of Nox1 function may provide an effective therapy for treating atherosclerosis, not just by decreasing oxidative burden but also by attenuating the molecular pathways that promote VSMC migration and atherosclerosis.
